FDA has indicated Merck‘s Recarbio for infections resulting from susceptible gram-negative microorganisms. The drug combines imipenem (a penem antibacterial), cilastatin (a renal dehydropeptidase inhibitor) and relebactam (a beta-lactamase inhibitor). Current FDA indications for the drug include hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, complicated urinary tract infections and complicated intra-abdominal infections.